+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid does not influence the number or distribution of desmin-positive non-parenchyma liver cells in rat biliary fibrosis



Ursodeoxycholic acid does not influence the number or distribution of desmin-positive non-parenchyma liver cells in rat biliary fibrosis



Journal of Gastroenterology & Hepatology 12(Suppl. ): A184




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144808

Download citation: RISBibTeXText


Related references

Anticholestatic effect of ursodeoxycholic acid is not accompanied by improved histology and decreased fibrosis in rat biliary liver fibrosis. Gastroenterology 112(4 Suppl. ): A1228, 1997

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32(6): 1196-1199, 2000

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. Journal of Hepatology 18(1): 9-14, 1993

Abnormalities in biliary drainage may predict a better response to ursodeoxycholic acid in cystic fibrosis-associated liver disease. Hepatology 24(4 Part 2): 201A, 1996

Ursodeoxycholic acid ameliorates parameters of cholestasis, but does not prevent collagen accumulation in rat secondary biliary liver fibrosis. Journal of Hepatology 26(Suppl. 1): 184, 1997

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 23(6): 1484-1490, 1996

Quantitative analysis of proliferating desmin positive and desmin negative perisinusoidal cells in fibrotic rat liver. Gastroenterology 100(5 Part 2): A771, 1991

Markedly decreased biliary ursodeoxycholic acid enrichment with high dose UDCA in cystic fibrosis associated liver disease Optimization of the therapeutic dose. Hepatology 20(4 Part 2): 262A, 1994

Greater biliary enrichment and improved liver tests with higher doses of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 120(5 Suppl. 1): A 574, 2001

Use of ursodeoxycholic acid in the treatment of hepato-biliary complications in cystic fibrosis. Pathologie-Biologie 39(6): 625-628, 1991

Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Digestive & Liver Disease 34(7): 523-527, 2002

The effect of ursodeoxycholic acid udca on liver function and bile acid metabolism in patients with cystic fibrosis cf and liver disease. Hepatology 10(4): 726, 1989

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 27(1): 166-174, 1998

The distribution and number of Leu-7 (CD57) positive cells in lung tissue from patients with pulmonary fibrosis. Acta Medica Okayama 56(2): 83-89, 2002

Comparison of intrahepatic vein-to-liver parenchyma and intercostal muscle-to-liver parenchyma strain ratios in the assessment of liver fibrosis: which one should we use?. Abdominal Imaging 40(4): 730-737, 2015